Four months after yielding first-in-human data INCA33890 enters phase 3.
ApexOnco Front Page
Recent articles
The company hands its PD-L1 x VEGF bispecific back to ImmuneOnco.
Lilly reveals that an Inluriyo/Verzenio combo is being limited to ESR1-mutant disease.
The group will start a pivotal trial of samuraciclib following promising second-line results.
The company leaves the door open for Trodelvy pre-chemo, despite Ascent-07’s failure.
Giredestrant’s adjuvant benefit looks similar to that of Kisqali and Verzenio.
Global phase 2 data in TNBC look similar to earlier results in China.
Studies presented at ASH show this to be true only up to a point.
